David Hunter, MD
Ophthalmology · Bluffton, SCNPI 1124311311
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.9%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 32.4% of the total. Reporting peaked in 2019 at $4,573 and has fallen 81.7% since, to $836 in 2025.
Across 255 payments — averaging $34.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$3K
- Glaukos Corporation$2K
- Sun Pharmaceutical Industries Inc.$978
- Alcon$883
- AbbVie$736
- Kala Pharmaceuticals, Inc.$563
- plus $1K from 16 others
What the payments were for
- Consulting fees$2,13224%
- Speaking & faculty fees$1,53218%
- Food & beverage$5,03958%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 27 | $2,819 |
| Glaukos Corporation | 7 | $1,681 |
| Sun Pharmaceutical Industries Inc. | 88 | $978 |
| Alcon | 27 | $883 |
| AbbVie(2 entities) | 37 | $736 |
| Kala Pharmaceuticals, Inc. | 28 | $563 |
| Biotissue Holdings Inc. | 4 | $290 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $145 |
| Rxsight Inc | 5 | $126 |
| Bausch & Lomb Americas Inc. | 6 | $120 |
| Novartis | 4 | $65 |
| Tarsus Pharmaceuticals, Inc. | 2 | $55 |
| Mallinckrodt Hospital Products Inc. | 2 | $47 |
| Sight Sciences, Inc. | 2 | $33 |
| Staar Surgical Company | 1 | $32 |
| Dompe US, Inc. | 1 | $26 |
| Thea Pharma Inc. | 1 | $22 |
| Eyevance Pharmaceuticals LLC | 1 | $20 |
| Ocular Therapeutix, Inc. | 1 | $17 |
| NEW World Medical,inc. | 1 | $17 |
| Lensar, Inc. | 1 | $16 |
| Rayner Intraocular Lenses Limited | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis Symfony IOL$2,132
- iStent inject Trabecular Micro-Bypass Stent System$1,500
- DURYSTA$125
- CEQUA$110
How this compares
$8,704 in reported general payments places this provider in the 85th percentile of 293 ophthalmology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 49 | $56,332 |
| CequaCyclosporine | 38 | $30,238 |
| XiidraLifitegrast | 11 | $15,346 |
| CombiganBrimonidine Tartrate/Timolol | 37 | $13,423 |
| LumiganBimatoprost | 21 | $13,161 |
| Cyclosporine | 20 | $13,001 |
| RocklatanNetarsudil Mesylat/Latanoprost | 16 | $9,733 |
| Prednisolone Acetate | 255 | $8,603 |
| Alphagan PBrimonidine Tartrate | 19 | $8,467 |
| VyzultaLatanoprostene Bunod | 14 | $7,607 |
| Brimonidine Tartrate | 232 | $7,344 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 31 | $5,555 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 268 | $4,328 |
| Timolol Maleate | 114 | $3,833 |
| RhopressaNetarsudil Mesylate | 12 | $3,741 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan, Alphagan P | $736 | $91,382126 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $978 | $30,23838 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $120 | $22,95325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 293 ophthalmology providers in South Carolina.
Other ophthalmology in Bluffton
- Kerry SolomonMt Pleasant$1.7M
- William ClarkWest Columbia$768K
- George WaringMt Pleasant$645K
- Karolinne RochaCharleston$552K
- Joseph BishopHilton Head Island$136K
- Erik HappMt Pleasant$124K
- Matthew ClaryColumbia$119K
- Kunal KanitkarLexington$83K
- Carl SloanMyrtle Beach$78K
- David VromanLadson$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.